Fiftyone Capital Update, page-5

First 5 Last

Share
Profile

Follow
Mozzarc

4,380 Posts.

6924

15/06/19

11:28

Post #: 39073146
Share

Originally posted by Mozzarc: ↑

I re-read this one last night, amazing, so this means there is potential for revenue without having to go through a Phase 3 trial? (see below quote from 51 Capital)
Did you guys realise that? How is this possible? Has it got to do with the fact that the DoD and the FDA are working together in this area?
Or is it more to do with the fact that this will be within the military and not the general public thus different rules and pathways can be followed?

I understand there is potential for revenue under the SAS through the TGA in Australia for OA and MPS, but revenue in regards to CHIKV will be quick if the DoD don't need a trial to occur. I agree, the market is completely overlooking this and the benefits and potential of iPPS totally! DOYR.

Potential DoD revenue from PAR maybe as soon as 2020?
The next stepis likely to start discussions with the US department of defence (DoD) who could start to purchase iPPS from Paradigm to treat service men and women who are suffering with chikungunya (CHIKV).

Thebest case is the DoD are happy with the results and safety and order anywherefrom $1m - $5m worth of product to begin treatments. Worst case, they want to run another trial inCHIKV and will either fund or co-fund this trial (which is not a badoutcome). There are thousands of service men and women with CHIKV and nocurrent treatment. Our estimates are a course of treatment would cost between$3000 - $5000 per treatment ($3-$5m per 1000 people).We rank the probability of purchasing before a trial at 50/50 odds – Given the strong safety profile and lack of alternative treatments there is a good chance they move forward with purchases. This is something the market seems to be completely overlooking.¹

Reference:

(1) http://www.fiftyonecapital.com/monthly-updates-1/2019/6/11/may-2019

Expand

STOP PRESS, just re-read the article (yes, third time) and in there it says revenue could come as early as July/August this year?
Im not getting my hopes up, I also want to say that 51 Cap rated it as a 50/50 chance of not needing a further trial, so to be conservative I'm still personally err'ing on the side of potential revenues in this stream (CHIKV) by next year sometime. My Opinions, but it sounds exciting to me.

PAR Price at posting: $1.43 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

What's causing the cost-of-living crisis, and how to navigate it

TLG

Talga Group wins key permit for flagship graphite mine in Sweden